Albendazole

證據等級: L5

預測適應症: 3 個

Albendazole: From Helminth Infections to Alveolar Echinococcosis

One-Sentence Summary

Albendazole is a broad-spectrum benzimidazole antiparasitic drug with established global efficacy against a wide range of helminth infections, currently not registered in Saudi Arabia. The TxGNN model predicts it may be effective for Alveolar Echinococcosis with a confidence score of 99.97%, supported by 5 clinical trials and 20 publications — including a completed Phase 2 RCT (n=194) directly testing albendazole in early-stage alveolar echinococcosis — making this the highest-priority repurposing candidate in the current dataset.

Quick Overview

Item	Content
Original Indication	Helminth infections (broad-spectrum antiparasitic; no Saudi Arabia market authorization on record)
Predicted New Indication	Alveolar Echinococcosis
TxGNN Prediction Score	99.97%
Evidence Level	L2
Saudi Arabia Market Status	Not Marketed
Number of Authorizations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Albendazole belongs to the benzimidazole class of anthelmintics. It acts by selectively binding to parasite β-tubulin with high affinity — an interaction far more potent than binding to human tubulin — thereby inhibiting microtubule polymerization. This disrupts the parasite's cytoskeletal integrity and blocks GLUT-mediated glucose uptake, leading to progressive glycogen depletion and energy starvation that ultimately paralyzes and kills the worm. The active metabolite, albendazole sulfoxide, is able to penetrate alveolar echinococcal cyst walls, ensuring therapeutic concentrations reach the Echinococcus multilocularis metacestode directly.

Alveolar echinococcosis (AE) is caused by the larval stage of E. multilocularis, a tapeworm (class Cestoda) that invades the liver with a pseudotumoral, infiltrative growth pattern. Without treatment, AE is nearly universally fatal within 10–15 years. Because E. multilocularis shares the same β-tubulin vulnerability as other cestode species, the mechanistic rationale for albendazole's anti-AE activity is well-founded. Albendazole functions as a parasitostatic agent in this context — it halts disease progression and suppresses cyst viability but does not achieve complete parasiticidal eradication — which is why surgical resection combined with long-term albendazole chemotherapy remains the standard of care.

Critically, the WHO has already listed albendazole as the first-line continuous chemotherapy for inoperable AE (administered in 28-day on / 14-day off cycles), and this use is endorsed by the WHO Informal Working Group on Echinococcosis (WHO-IWGE) expert consensus guidelines. This is therefore an established, guideline-supported use rather than a speculative repurposing hypothesis. However, since albendazole is not currently marketed in Saudi Arabia, accessing this treatment requires a formal import authorization or compassionate-use pathway — making the TxGNN prediction clinically and regulatorily actionable in this market context.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT07182305	Phase 2	Completed	194	Direct RCT testing albendazole for early-stage AE in an endemic region of Kyrgyzstan (Osh province). Most prior evidence focused on late or inoperable cases; this trial specifically addresses early-stage intervention. Highest-quality direct clinical evidence for this indication to date.
NCT02876146	N/A	Completed	50	Prospective observational cohort (EchinoVISTA) of AE patients on albendazole, evaluating parasite viability markers and imaging-based criteria to guide treatment withdrawal decisions. Supports development of a structured monitoring framework for long-term therapy.
NCT06483880	N/A	Unknown	24	RCT evaluating adjuvant albendazole vs. placebo after pulmonary hydatid cyst (cystic echinococcosis, CE) surgical resection to reduce 6-month recurrence. CE and AE share the same drug mechanism; findings can be indirectly extrapolated to adjuvant AE scenarios.
NCT05824442	N/A	Recruiting	43	Evaluation of a new multiplex qPCR diagnostic technique for echinococcosis. Not a treatment efficacy trial; albendazole is mentioned as the standard of care backdrop. No direct contribution to albendazole efficacy assessment.
NCT07176598	N/A	Completed	1	Case report of a rare intramuscular (deltoid) hydatid cyst initially misdiagnosed as a synovial cyst. Lowest-grade evidence; useful only for reference in rare extra-hepatic anatomical presentations.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
19931502	2010	Expert Consensus Guidelines	Acta Tropica	WHO-IWGE consensus on diagnosis and treatment of cystic and alveolar echinococcosis; formally establishes albendazole as the standard of care for inoperable AE with 28-day on/14-day off cycling regimen. Foundational reference for all clinical practice.
39254012	2024	Review	Tidsskrift for Den Norske Lægeforening	Contemporary review of AE epidemiology, diagnosis, and management; highlights the pseudotumoral liver presentation, the role of prolonged albendazole therapy, and emerging risk in previously non-endemic regions, relevant to Saudi Arabia import risk assessment.
30760475	2019	Review	Clinical Microbiology Reviews	Comprehensive overview of 21st-century advances in echinococcosis including genetics, diagnostics, and treatment. Discusses albendazole bioavailability limitations, resistance concerns, and emerging alternatives. Widely cited benchmark review.
40093668	2025	Review	World Journal of Gastroenterology	Current management of hepatic echinococcosis; emphasizes surgery as the cornerstone with albendazole chemotherapy as adjuvant or sole option when surgical cure is not achievable. Affirms continued dependence on albendazole in 2025.
34161992	2021	Review	Seminars in Liver Disease	Focused review of hepatic AE: pathophysiology, staging, and treatment outcomes. Reports that the combination of earlier diagnosis, improved surgery, and prolonged albendazole use has transformed the AE prognosis since the 1990s.
39311470	2024	Review	Parasite (Paris)	Status review of chemotherapy for AE: identifies that benzimidazoles remain the only recommended class but highlights limitations — parasitostatic only, potential hepatotoxicity with prolonged use, and variable bioavailability. Points to unmet need for parasiticidal options.
39508157	2024	Drug Repurposing Review	Parasitology	Identifies pyronaridine (an approved antimalarial) via drug repurposing as a promising candidate to supplement or replace albendazole in hard-to-treat AE. Confirms that albendazole is currently the exclusive standard pharmacological treatment, underscoring the therapeutic gap.
38501660	2024	Pharmacological Study	Antimicrobial Agents and Chemotherapy	Develops and evaluates bioavailability-enhancing albendazole formulations (crystalline dispersion, hydrochloride, and hydroxyethyl sulfonate composites) in a hepatic AE rat model. Addresses low oral bioavailability as a key barrier to optimal therapeutic outcomes.
34808118	2022	Review	Acta Tropica	Review of novel treatment options for CE and AE; confirms that no licensed non-surgical alternative to albendazole or mebendazole currently exists, reinforcing the continued clinical necessity of albendazole access.
36974024	2022	Review	Chinese Journal of Schistosomiasis Control	Progress summary of albendazole use for AE treatment; documents the parasitostatic mechanism, long-term treatment outcomes, and emerging research on improved dosing strategies and potential combination therapies to overcome treatment failure in >20% of patients.

Saudi Arabia Market Information

Albendazole currently has no registered authorizations with the Saudi Food and Drug Authority (SFDA). There are no licensed products available on the Saudi market. Patients in Saudi Arabia who require albendazole therapy for alveolar echinococcosis must access the drug through one of the following pathways:

Compassionate use / named-patient import from a country where the drug is registered (e.g., United Kingdom, France, United States)
Unlicensed import authorization via SFDA Special Access Scheme
Procurement through international humanitarian/WHO channels (albendazole is on the WHO Essential Medicines List)

Safety Considerations

Please refer to the package insert for safety information.

Notice: Formal safety data including specific warnings, contraindications, and drug interaction profiles were not available in the current dataset. Albendazole has an established global safety profile and is a WHO Essential Medicine; however, prolonged high-dose use (as required for AE) carries hepatotoxicity risk. Clinicians should consult the manufacturer's current prescribing information, WHO treatment guidelines, and the WHO-IWGE expert consensus before initiating therapy. Baseline and periodic liver function monitoring is standard practice in AE treatment protocols.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: A completed Phase 2 RCT (NCT07182305, n=194) directly testing albendazole in early-stage alveolar echinococcosis, combined with WHO designation as first-line therapy for inoperable AE, robust mechanistic evidence (selective β-tubulin binding → parasite energy depletion), and broad international guideline support, constitutes L2-level evidence sufficient to support use. The primary barrier in Saudi Arabia is not efficacy or safety uncertainty — both are well-characterized globally — but rather regulatory access, since the drug is not currently marketed in the Kingdom.

To proceed, the following is needed:

Regulatory pathway: Initiate SFDA special access or compassionate use application; identify a registered-country supplier for importation
Safety data package: Obtain the current manufacturer's package insert to formally document warnings, contraindications, and drug-drug interactions (particularly with CYP enzyme inducers/inhibitors that affect albendazole sulfoxide plasma levels)
Long-term monitoring plan: Establish a protocol for liver function tests (ALT/AST, total bilirubin), CBC (including differential), and renal function at baseline and at regular intervals throughout extended therapy — AE typically requires months to years of continuous treatment
Multidisciplinary team: Engage hepatology, infectious disease, and/or parasitology specialists for staging, treatment decision-making, and surgical consultation (R0 resection with adjuvant albendazole offers the best outcome when feasible)
Imaging infrastructure: Confirm access to MRI/CT (and ideally PET-CT) for baseline staging and treatment response assessment per WHO-IWGE criteria (PNM staging system)
Patient counseling: Inform patients that albendazole is parasitostatic — not parasiticidal — in AE; indefinite or lifelong therapy may be required in inoperable cases
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.